"Johnson & Johnson's Q4 revenue reached $24.56B, up 9.1% year over year, driven by Innovative Medicine, which generated $15.76B, a 10% increase. Key products like DARZALEX and TREMFYA saw remarkable growth, with DARZALEX at $3.90B, up 26.6%, and TREMFYA surging 67.6% to $1.58B."
"Coca-Cola's revenue for Q4 was $11.82B, missing the consensus estimate by 2.7%. Despite this, organic revenue grew by 5%, with Coca-Cola Zero Sugar achieving a 13% increase in unit case volume for Q4 and 14% for the full year."
Johnson & Johnson reported Q4 revenue of $24.56B, exceeding estimates, driven by strong performance in Innovative Medicine. Key products like DARZALEX and TREMFYA showed significant growth. The company is investing over $55B in various healthcare sectors and aims for $100.5B in revenue by 2026. In contrast, Coca-Cola's Q4 revenue of $11.82B fell short of expectations, despite a 5% organic growth. Coca-Cola is focusing on brand strength and refranchising to an asset-light model, divesting bottling operations to enhance profitability.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]